Obesity Clinical Trial
Official title:
Intensive Lifestyle Modifications With or Without Liraglutide 3 mg Versus Sleeve Gastrectomy: A 3 Arm Randomized Controlled Pilot Study (LETHE)
Background/Objectives: Only 1% of the clinically eligible subjects receive surgical treatment
for their obesity, thus other options should be investigated. In this study we aim to assess
the effect of intensive-lifestyle-modification(ILM) with or without Liraglutide-3mg daily
versus sleeve-gastrectomy(SG) on BMI at 1-year.
Subjects/Methods: In this study performed in a University Hospital in Italy, non-diabetic
patients eligible for bariatric-surgery are recruited from the weight loss clinic and have
the option to choose within three possible weight-loss programs up to complete the allocation
of 25 subjects in each arm matched by BMI and age. ILM consists in 600kcal
very-low-calorie-diet(VLCD) for 1 month followed by 12kcal/kgbw high-protein, high-fat-diet
for 11 months plus 30minutes brisk-walk daily and at least 3 hours aerobic-exercise weekly.
SG patients have 1-month VLCD and free-diet thereafter. Patients are evaluated at baseline
and at 1,3,6,9 and 12months.
Obesity is associated with major chronic diseases, including type 2 diabetes (T2D) and
cardiovascular disease (CVD) 1-3. The number of subjects affected by morbid obesity or class
III obesity (BMI≥40 kg/m2) is rapidly increasing 4 and contributed to 20% of the total per
capita health-care expenditures in 2000 in the United States 5 .
Subjects with a body mass index (BMI) >40 kg/m2 or >35 kg/m2 in the presence of obesity
complications are eligible for bariatric surgery 6 . The mortality rate after bariatric
surgery is low, being 0.08% within 30 days and 0.31% after 30 days 7, and bariatric surgery
has shown many health benefits including reduction of long term mortality 8 and type 2
diabetes remission (T2D) 9-11., However, due to the perception that bariatric surgery is a
risky procedure among the general public and insurance companies or other health care
providers only 1% of the clinically eligible subjects receive surgical treatment for their
obesity 12.
The largest portion of patients eligible for bariatric surgery but who are not willing to be
operated or cannot undergo surgery for other reasons should be offered, however, with other
therapeutic options. To this end a pilot study to determine the efficacy of an intensive
lifestyle modification (ILM) with or without 3 mg daily Liraglutide versus bariatric surgery
with free diet and free physical activity was designed. In the medical arms the patients were
also invited to contact the dietitian and the physician every week by email or by phone to
assure a tight weight control. The allocation of the patients, all of them eligible for
bariatric surgery, was on a voluntary basis, i.e. they were invited to decide their
allocation in one of the 3 arms of the study matched by BMI and age.
Liraglutide, a glucagon-like peptide-1 analog, approved for the treatment of obesity at the
dose of 3 mg per day and commercialized under the name of Saxenda, was proved to reduce body
weight after 56 weeks by 8.4±7.3 kg as compared with a mean of 2.8±6.5 kg in the patients
under placebo 13 . Importantly, the weight reduction is maintained up to 3 years as shown by
LeRoux et al. 14.
However, this degree of weight loss is generally considered insufficient by patients who
would like to be considered for bariatric surgery.
A 12 week VLCD was reported to allow a weight reduction of about 20 kg in men and of near 16
kg in women 15. However, the weight-reducing effect of a VLCD is temporary and must be
combined with other methods to maintain the weight loss. Low-carbohydrate, high-fat,
high-protein diet is associated with a relevant weight loss and elevated satiating effects as
well as with maintenance or accretion of lean body mass 16,17.
In this study it was hypothesized that a VLCD for 1 month might match in the two medical arms
the weight loss reached with SG, thus giving more motivation to the patients to continue the
diet. The aim of the study is to find other avenues than bariatric surgery to treat obese
patients obtaining a relevant weight loss that can satisfy morbidly obese subjects.
Therefore, this trial included a VLCD for the first month in order to match the diet usually
prescribed after bariatric surgery and the following diet will be a low-carbohydrate,
high-fat, high-protein diet to achieve a substantial weight loss.
Among the surgical procedures sleeve gastrectomy (SG) was chosen since it has increased
markedly in the past few years and has earned a place as a primary bariatric surgery 18.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |